RenovoRx (RNXT) Price to Sales (2025 - 2026)
RenovoRx's (RNXT) quarterly Price to Sales came in at 48.65 in Q2 2026, down 57.56% year-over-year from 114.63 in Q2 2025, and down 39.81% quarter-over-quarter from 80.82 in Q1 2026.
Powered by 
Analysis
RenovoRx (RNXT) Price to Sales (2025 - 2026) Analysis & Trends
RenovoRx has disclosed Price to Sales across 2 years of filings, most recently posting 48.65 for Q2 2026.
- In Q2 2026, Price to Sales fell 57.56% year-over-year to 48.65; the TTM figure through Jun 2026 stood at 22.38 (changed N/A YoY), while the FY2025 annual figure was 27.39, down 96.2% from the prior year.
- Price to Sales came in at 48.65 for Q2 2026 at RenovoRx, down from 80.82 in the prior quarter.
- In the past five years, Price to Sales ranged from a high of 183.66 in Q1 2025 to a low of 48.65 in Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 179.84 Bn | 174.23 Bn | 7.27 Bn |
| 2 | Intuitive Surgical | 128.02 Bn | 122.81 Bn | 1.96 Bn |
| 3 | Medtronic | 117.28 Bn | 108.46 Bn | 6.34 Bn |
| 4 | Stryker | 103.92 Bn | 100.44 Bn | 4.50 Bn |
| 5 | Boston Scientific | 63.51 Bn | 62.97 Bn | 3.85 Bn |
| 6 | Edwards Lifesciences | 49.96 Bn | 45.70 Bn | 1.35 Bn |
| 7 | Alcon | 32.86 Bn | 31.40 Bn | 1.68 Bn |
| 8 | Dexcom | 32.25 Bn | 30.30 Bn | 830.00 Mn |
| 9 | Steris | 20.74 Bn | 20.26 Bn | 684.20 Mn |
| 10 | RenovoRx | 82.06 Mn | 82.06 Mn | 766,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 48.65 |
| Mar 31, 2026 | 80.82 |
| Dec 31, 2025 | 129.23 |
| Sep 30, 2025 | 174.98 |
| Jun 30, 2025 | 114.63 |
| Mar 31, 2025 | 183.66 |